Viropharma — Investor Day (October 2006)
34 slides from Viropharma's investor day presentation, Oct 25, 2006
Slide 1: Cytomegalovirus in the Transplant Setting and Beyond: Disease Today; Prevention Tomorrow
Exhibit 99.1 Cytomegalovirus in the Transplant Setting and Beyond: Disease Today; Prevention Tomorrow Wednesday, October 25, 2006 Hotel Intercontinental (The Barclay), New York City 1
Slide 2: Dynamics of the CMV Transplant Market
CH3 H3C N C HN N C HO O HO OH Dynamics of the CMV Transplant Market Vincent Milano ViroPharma Incorporated 2
Slide 3: Forward-looking statements
This presentation contains certain forward-looking statements that involve risks and uncertainties. Actual results and events may differ significantly from results and events discussed in forward-looking statements. Factors that might cause or contribute to such differences include, but are not limi
Slide 4: Maribavir
Maribavir • $400 to $500M WW peak year product potential • Worldwide rights, excluding Japan • Expect to file NDA in 2009 • ‘Composition of Matter’ patent expires 2015 – Opportunity for Hatch-Waxman patent term extension • Highly concentrated market of ‘target physicians’ • Evident medical need with
Slide 5: Strong Market Performance by Current CMV Therapeutics
Strong Market Performance by Current CMV Therapeutics Val/Ganciclovir sales in CMV are >$300M per year, despite ‘Black Box’ toxicities $350,000,000 $300,000,000 $250,000,000 $200,000,000 $150,000,000 $100,000,000 $50,000,000 $0 5
Slide 6: Number of U.S. Transplants Increases by Over 3 Percent Per Year
Number of U.S. Transplants Increases by Over 3 Percent Per Year ESTIMATED USA ESTIMATED USA TRANSPLANTS TRANSPLANTS (2005) (2004) GROWTH SCT/BMT 17,700 17,500 1.1% SOT LIVER 6,445 6,129 5.2% SOT KIDNEY 16,477 16,002 3.0% SOT HEART 2,127 2,016 5.5% SOT OTHER 3,223 2,848 13.2% Why? Trends in transplan
Slide 7: Transplant Represents a Highly Concentrated Market
Transplant Represents a Highly Concentrated Market • 255 transplant centers in the US operate one or more organ transplant programs: 300 250 200 US Transplant Programs Unos March 05 150 100 50 0 Heart- Intestine Liver Pancreas Heart Kidney Lung Pancreas Lungs Islet Cell • The top 100 centers cover 7
Slide 8: Transplant: An "Innovator" Market
Transplant: An “Innovator” Market Rapid Uptake Immunosupressants – IMS Sales 1992 to 2004 CYCLOSPORINE-EON $45,000,000 $700,000,000 CYCLOSPORINE-PLI $40,000,000 $600,000,000 CYCLOSPORINE-ATX $35,000,000 $500,000,000 $30,000,000 CYCLOSPORINE-RKG $25,000,000 $400,000,000 ORTHOCLONE OKT-3 -OBD Rapid $2
Slide 9: Fast Adoption Patterns in the Transplant World
Fast Adoption Patterns in the Transplant World CMV Agents – IMS Sales $18,000,000 $160,000,000 FOSCAVIR On $16,000,000 $140,000,000 Foscavir primary $14,000,000 axis $120,000,000 GANCICLOVIR (LEFT) $12,000,000 Generic - oral $100,000,000 $10,000,000 $80,000,000 $8,000,000 $60,000,000 CYTOVENE On $6,
Slide 10: Allogeneic Stem Cell Transplant
Allogeneic Stem Cell Transplant • Allogeneic SCT is of highest risk for CMV disease • <25 percent of SCT centers practice prophylaxis, 75 percent pre-emptive • Market research suggests that most physicians would switch from pre- emptive to prophylaxis with proven, equally effective, less toxic agent
Slide 11: Solid Organ Transplant
Solid Organ Transplant • Current CMV antivirals: oral / IV ganciclovir, oral valganciclovir, IV foscarnet, and IV cidofovir. • Most US centers use prophylaxis (75 percent) over pre-emptive for SOT patients • The main concern with ganciclovir prophylaxis is that CMV infection may only be delayed or G
Slide 12: Therapeutic Strategies for the Management of CMV
Therapeutic Strategies for the Management of CMV Prophylaxis Definitive Treatment Universal Targeted Pre-emptive Deferred Prophylaxis Prophylaxis Treatment Treatment Same prophylaxis Administered to Administered to Treatment regimen high-risk patients patients with initiated after administered to fo
Slide 13: Universal Prophylaxis vs. Pre-emptive Therapy
Universal Prophylaxis vs. Pre-emptive Therapy A meta-analysis to assess the efficacy of universal prophylaxis and pre- emptive approaches in prevention of CMV disease and other complications in SOT recipients 1 0.9 • Compared with placebo or 0.8 no treatment, both strategies 0.7 0.6 reduced CMV orga
Slide 14: Other Populations at High Risk of CMV Disease
Other Populations at High Risk of CMV Disease • CMV retinitis in HIV patients: 3 – Approx 85,000 at-risk patients with CD4 counts below 50 cells/mm – Up to 30,000 HIV/AIDS patients develop CMV retinitis each year • CMV disease in neonates: – ~6,000 symptomatic at birth – Children born with high vira
Slide 15: Maribavir
CH3 H 3C N C HN N C HO O HO OH Maribavir Colin Broom, MD ViroPharma Incorporated 15
Slide 16: Maribavir for Prophylaxis Against CMV in Recipients of Allogeneic Stem Cell Transplants
CH3 H 3C N C HN N C HO O HO OH Maribavir for Prophylaxis Against Cytomegalovirus in Recipients of Allogeneic Stem Cell Transplants Preliminary Results of a Phase 2 study 16
Slide 17: Maribavir Preclinical Data
Maribavir Preclinical Data CH3 • Chemical class: Benzimidazole H 3C N Cl HN • Orally bioavailable N Cl • Mechanism: HO Inhibit UL97 viral protein kinase O – Inhibit viral encapsidation HO – Inhibit nuclear egress of viral particles OH • Unlike other anti-CMV agents, maribavir does not affect the UL5
Slide 18: Phase 2 Study Design
Phase 2 Study Design • Randomized, double-blind, placebo-controlled, dose-ranging study • Adult CMV-seropositive recipients of allogeneic SCT • After transplant engraftment, subjects randomized to receive oral placebo or maribavir at doses of: – 100 mg BID; 400 mg QD; 400 mg BID • Duration of dosing
Slide 19: Phase 2 Study Design
Phase 2 Study Design Study Drug Administration Screening (Maximum 12 weeks) Follow-Up (No CMV detected) Wk Wk Wk Study Drug 1 4 8 Engraftment SCT (14-30 days) Study Drug Pre-emptive Rx* CMV + Randomization * Management of CMV infection or to Maribavir or disease as per standard practice Placebo at t
Slide 20: Baseline Characteristics
Baseline Characteristics Intent-to-treat (ITT) Population Placebo 100 mg BID 400 mg QD 400 mg BID N 28 28 28 27 Age (y) Median 43 46 48 51 Gender (% male) 54% 61% 64% 37% SCT Type: Myeloablative 71% 79% 61% 70% Non-myeloablative 29% 21% 39% 30% 20
Slide 21: Phase 2 CMV Infection or Disease
Phase 2 CMV Infection or Disease Within 100 Days Post-transplant, ITT Placebo 100 mg BID 400 mg QD 400 mg BID N 28 28 28 27 † Evaluable 28 27 27 26 CMV infection as assessed by: CMV Disease** 11% 0 0 0 pp65 Ag 39% 15%* 19% 15% DNA PCR 46% 7%* 11%* 19%* Initiation of anti-CMV treatment 57% 15%* 30% 1
Slide 22: Phase 2 Tolerability
Phase 2 Tolerability The tolerability profile of maribavir was very favorable in this complex patient population: • Most AEsoccurred at similar rates in maribavir and placebo groups • Consistent with prior clinical studies, the most notable events adverse were taste disturbance and nausea (generally
Slide 23: Maribavir: Phase 2 Study Conclusions
Maribavir: Phase 2 Study Conclusions • Including the follow up period, there were casesnoof CMV disease in any maribavir group, compared to 11 percent of patients in the placebo (preemptive therapy only) group; • Maribavir prophylaxis reduced the rate of CMV infection compared to the placebo (preemp
Slide 24: Maribavir Phase 3 Study in SCT
Maribavir Phase 3 Study in SCT • Randomized,double-blind, placebo-controlled, multicenter pivotalPhase3 study in 500 allogeneic SCT patients • 2:1 randomization ratio. – Patients will receive maribavir 100 mg BID or placebo for up to 12 weeks. • Enrolled subjects will undergo testing for CMV infecti
Slide 25: Maribavir 2007
Maribavir 2007 What studies are expected to be ongoing during 2007? • Phase 3 in SCT (initiated 3Q ‘06) • Phase 3 in SOT (liver) • Phase 2(s) in further SOT populations • Phase 2 pre-emptive treatment in SCT • Phase 1 studies to supplement pharm clin package – Including co-administration of tacrolim
Slide 26: Other Populations at Increased Risk of CMV Disease
CH3 H3C N C HN N C HO O HO OH Other Populations at Increased Risk of CMV Disease 26
Slide 27: CMV Retinitis in HIV Patients
CMV Retinitis in HIV Patients • HIV patients in the world: 36.3 million adults and 2.3 million children – Approximately 30% have AIDS • Number of U.S. patients with AIDS: 415,000 (CDC), growing at 4 percent/year • At risk of CMV disease if CD4 count <50 cells/mm3 (17-20 of percent patients) • 19-25
Slide 28: CMV Retinitis in HIV Patients: Today's Treatment Paradigm
CMV Retinitis in HIV Patients Today’s Treatment Paradigm • The average duration of a CMV retinitis episode/treatment: 6 months • IV ganciclovir, foscarnet, and cidofovir all shown to improve CMV retinitis – Ganciclovir and foscarnet can also be given as intravitreal implants • ~25 to 35 percent of p
Slide 29: The Neonatal CMV Market
The Neonatal CMV Market Pregnant Women in the US (4,000,000) 55% to 85% 15% to 45% are CMV are CMV seropositive seronegative 0.1% to 1% 1% to 10% experience a recurrent maternal experience a primary infection infection that produces a 40% of these produce a congenitally infected newborn congenitally
Slide 30: The Neonatal CMV Market: Today's Treatment Paradigm
The Neonatal CMV Market Today’s Treatment Paradigm • Congenital CMV is now high priority at the CDC with the CMV Congenital Prevention Workgroup • Current treatment is with ganciclovir IV for 42 days • Because of marrow and kidney toxicities, GCV is reserved to the most severe of symptomatic patient
Slide 31: CMV in Oncology
CMV in Oncology • Reported incidence of infection and disease in overall cancer population is 0.2-2 percent. • Both incidence and prevalence during chemotherapy depend on the type of cancer and type of treatment – Lymphomas: 9 to 22 percent CMV infections, 3 percent get CMV disease – A significant n
Slide 32: CMV in Oncology: Today's Treatment Paradigm
CMV in Oncology Today’s Treatment Paradigm • Most oncology patients who develop a CMV infection or CMV disease have blood cancers (93,000 per yearincludes – some overlapwithtransplant ) patients • Current treatment: 30 to 90 days Valganciclovir (treatment with CAMPATH may lead to longer anti-CMV mai
Slide 33: Conclusion
CH3 Conclusion H3C HN N N C C HO O HO OH • Significant risk of CMV reactivation and disease in growing transplant population • Unmet medical need for new, innovative, better tolerated anti-CMV agents for transplant patients • Market responsive to innovative products • Current therapies exceed $300M
Slide 34: Thank You
CH3 Thank You H3C HN N N C C HO O HO OH 34